Abstract
We carried out a fine-mapping study in the HNF1B gene at 17q12 in two study populations and identified a second locus associated with prostate cancer risk, ∼26 kb centromeric to the first known locus (rs4430796); these loci are separated by a recombination hot spot. We confirmed the association with a SNP in the second locus (rs11649743) in five additional populations, with P = 1.7 × 10−9 for an allelic test of the seven studies combined. The association at each SNP remained significant after adjustment for the other SNP.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Gudmundsson, J. et al. Nat. Genet. 39, 977–983 (2007).
Eeles, R.A. et al. Nat. Genet. 40, 316–321 (2008).
Thomas, G. et al. Nat. Genet. 40, 310–315 (2008).
Zheng, S.L. et al. N. Engl. J. Med. 358, 910–919 (2008).
Sun, J. et al. Prostate 68, 691–697 (2008).
Yeager, M. et al. Nat. Genet. 39, 645–649 (2007).
Gudmundsson, J. et al. Nat. Genet. 39, 631–637 (2007).
Haiman, C.A. et al. Nat. Genet. 39, 638–644 (2007).
Zheng, S.L. et al. J. Natl. Cancer Inst. 99, 1525–1533 (2007).
Amundadottir, L.T. et al. Nat. Genet. 38, 652–658 (2006).
Freedman, M.L. et al. Proc. Natl. Acad. Sci. USA 103, 14068–14073 (2006).
Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. Nat. Genet. 39, 906–913 (2007).
Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. Bioinformatics 21, 263–265 (2005).
Gabriel, S.B. et al. Science 296, 2225–2229 (2002).
Fearnhead, P. et al. Bioinformatics 22, 3061–3066 (2006).
Acknowledgements
We thank all the study subjects who participated in this study. We also thank the Regional Cancer Registries and the CAPS-steering committee, including E. Varenhorst. We acknowledge the support of W.T. Gerrard, M. Duhon, Jennifer and John Chalsty and D. Koch. We also thank the National Cancer Institute Cancer Genetic Markers of Susceptibility Initiative (CGEMS) for making the data available publicly. We take full responsibility for the study design, data collection, analysis and interpretation of the data, the decision to submit the manuscript for publication, and the writing of the manuscript. The study is supported by National Cancer Institute (CA106523, CA106523 and CA95052 to J.X., CA112517, CA58236 to W.B.I., CA86323 to A.W.P., Department of Defense grant PC051264 to J.X.), as well as support from Swedish Cancer Society (Cancerfonden) and Swedish Research Council to H.G.
Author information
Authors and Affiliations
Contributions
J.X., W.B.I., H.G., J.C., D.D. and J.M.T. designed and directed the study. S.L.Z. directed genotyping. Jielin Sun, F.W., F.-C.H., S.-T.K., Y.Z., L.D., Jishan Sun, J.L., B.-L.C. and J.X. conducted data analysis. S.D.I., K.E.W., B.J.T., A.W.P., P.C.W. and W.B.I. were involved in the sample collection at Johns Hopkins Hospital. P.S., H.-O.A., J.A., J.-E.J. and H.G. were involved in the sample collection in Sweden. L.D.P., Z.G., W.L. and T.L. performed laboratory analyses. A.R.T. and T.S.A. provided administrative and technical support for the study.
Corresponding authors
Supplementary information
Supplementary Text and Figures
Supplementary Methods, Supplementary Tables 1–6, Supplementary Figure 1 (PDF 1008 kb)
Rights and permissions
About this article
Cite this article
Sun, J., Zheng, S., Wiklund, F. et al. Evidence for two independent prostate cancer risk–associated loci in the HNF1B gene at 17q12. Nat Genet 40, 1153–1155 (2008). https://doi.org/10.1038/ng.214
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.214
This article is cited by
-
Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG
Nature Communications (2022)
-
Analysis of expression, epigenetic, and genetic changes of HNF1B in 130 kidney tumours
Scientific Reports (2020)
-
HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer
Oncogene (2020)
-
HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study
Scientific Reports (2020)
-
Cumulative evidence for relationships between multiple variants of HNF1B and the risk of prostate and endometrial cancers
BMC Medical Genetics (2018)